Retrophin CEO Was Told Of Shady Shkreli Deals, Jury Hears

Law360, New York (July 14, 2017, 10:15 PM EDT) -- The CEO and board member of Retrophin Inc. on Friday confirmed to a Brooklyn jury he received messages early on regarding settlement agreements in which the company picked up the tab for former CEO Martin Shkreli’s debt to investors, despite testifying earlier that the deals were never discussed or approved.

Retrophin head Stephen Aselage, 66, who took over the reins of the pharmaceutical company after Shkreli resigned under pressure in late 2014, testified for the second day in the securities fraud trial over allegations that Shkreli...
To view the full article, register now.